My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

555.51 -21.47 (-3.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,394,244
Open 577.30
Bid (Size) 556.90 (1)
Ask (Size) 558.45 (2)
Prev. Close 576.98
Today's Range 549.20 - 579.00
52wk Range 476.49 - 1,080.00
Shares Outstanding 91,779,465
Dividend Yield 0.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Regeneron (REGN) Shares Are Falling Today
Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.1% in the afternoon session after the company highlighted challenges, including regulatory approvals and competitive pressures, at a healthcare... 
Via StockStory
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga

Performance

YTD
-22.3%
-22.3%
1 Month
-2.9%
-2.9%
3 Month
+6.8%
+6.8%
6 Month
-13.2%
-13.2%
1 Year
-46.9%
-46.9%

More News

Read More
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question
Via StockStory
What Does the Market Think About Regeneron Pharmaceuticals?
Via Benzinga
Why Regeneron (REGN) Stock Is Down Today
Via StockStory
Wall Street Pauses For A Breather, Small Caps Soar: What's Moving Markets Tuesday?
Via Benzinga
Discover which S&P500 stocks are making waves on Tuesday.
Via Chartmill
Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection
Via Benzinga
Tuesday's session: gap up and gap down stock in the S&P500 index
Via Chartmill
1 S&P 500 Stock on Our Buy List and 2 We Turn Down
Via StockStory
Topics Stocks
FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Via Benzinga
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
REGENERON PHARMACEUTICALS (NASDAQ:REGN) Screens as a Top Value Stock with Strong Fundamentals
Via Chartmill
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?
Via Investor's Business Daily
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
1 Cash-Heavy Stock to Research Further and 2 We Brush Off
Via StockStory
Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder
Via Benzinga
Topics Death
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
Via MarketMinute
Topics Economy Government World Trade
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
Via Benzinga
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Cash-Producing Stocks That Concern Us
Via StockStory

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 555.51
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 09/25/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 50.98B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 51B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.